TCBI:NASDAQTexas Capital Bancshares, Inc. Analysis
Data as of 2026-08-02 - not real-time
$98.85
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Texas Capital Bancshares (TCBI) is trading at $98.85, roughly half its DCF‑derived fair value of $207, indicating substantial undervaluation. The stock’s price‑to‑earnings multiple of 12.9 is well below the industry average of 18.0, reinforcing the value case. Revenue grew 8.6% YoY and adjusted EPS rose 15% in Q2, driven by record fee income and commercial loan expansion. Operating margin stands at 36.7% and profit margin at 28.7%, showcasing robust profitability for a regional bank. The dividend yield of 0.81% is supported by an extremely low payout ratio of ~2.6%, suggesting sustainability. Technical indicators show a bullish long‑term trend (price above the 200‑day SMA) but a bearish short‑term MACD and price below the 20‑day SMA, implying near‑term caution.
RSI at 42 points to neither overbought nor oversold conditions, while volume is increasing, adding confidence to the upside. The 30‑day volatility of 23.8% and beta near 0.9 indicate moderate market sensitivity, typical for regional banks. The fear‑greed index at 92.9 (“Extreme Greed”) reflects a broadly risk‑on environment that could lift financial stocks. With a support level near $96.96 and resistance at $107.78, the stock has room to rally toward the analyst consensus target around $109‑110. The strategic partnership with Phoenix Merchant Partners expands its alternative asset platform, potentially enhancing fee‑based revenue streams. Overall, the combination of strong fundamentals, attractive valuation, and a favorable macro backdrop supports a buy recommendation for investors with a medium‑to‑long horizon.
RSI at 42 points to neither overbought nor oversold conditions, while volume is increasing, adding confidence to the upside. The 30‑day volatility of 23.8% and beta near 0.9 indicate moderate market sensitivity, typical for regional banks. The fear‑greed index at 92.9 (“Extreme Greed”) reflects a broadly risk‑on environment that could lift financial stocks. With a support level near $96.96 and resistance at $107.78, the stock has room to rally toward the analyst consensus target around $109‑110. The strategic partnership with Phoenix Merchant Partners expands its alternative asset platform, potentially enhancing fee‑based revenue streams. Overall, the combination of strong fundamentals, attractive valuation, and a favorable macro backdrop supports a buy recommendation for investors with a medium‑to‑long horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below 20‑day SMA and bearish MACD signal short‑term weakness
- Support level near $96.96 provides downside cushion
- Increasing volume suggests potential for a near‑term bounce
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervaluation relative to DCF and industry PE
- Strong operating margins and fee‑income growth
- Strategic partnership expanding fee‑based revenue
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable dividend with ultra‑low payout ratio
- Long‑term bullish trend (price above 200‑day SMA)
- Robust capital position and low leverage
Key Metrics & Analysis
Financial Health
Revenue Growth8.60%
Profit Margin28.70%
P/E Ratio12.9
ROE10.19%
ROA1.11%
P/B Ratio1.3
Op. Cash Flow$487.8M
Industry P/E18.0
Technical Analysis
TrendBullish
RSI41.7
Support$96.96
Resistance$107.78
MA 20$101.89
MA 50$101.25
MA 200$96.37
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88
Valuation
Fair Value$207.10
Target Price$109.31
Upside/Downside10.58%
GradeUndervalued
TypeBlend
Dividend Yield0.81%
Risk Assessment
Beta0.94
Volatility23.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.